Immune therapy in type 1 diabetes mellitus

Area of Science:

• Immunology
• Endocrinology
• Genetics

Background:

• Type 1 diabetes mellitus (T1DM) is an autoimmune disease targeting pancreatic beta cells, with genetic links to HLA-DQ alleles and unknown environmental factors.
• Islet autoimmunity, marked by autoantibodies, can be present in young children, indicating early disease processes.
• T1DM diagnosis in first-degree relatives is uncommon, highlighting the complex interplay of genetic predisposition and environmental triggers.

Purpose of the Study:

• To review current immune therapy approaches for Type 1 diabetes mellitus (T1DM) at different stages of the disease.
• To highlight ongoing clinical trials and research into novel therapeutic strategies for T1DM.
• To emphasize the need for therapies that prevent or halt beta-cell destruction.

Main Methods:

• Review of primary prevention strategies targeting genetically predisposed individuals.
• Analysis of secondary prevention trials for individuals with persistent islet autoantibodies.
• Examination of interventions at T1DM onset, including nonautoantigen-specific and autoantigen-specific therapies.

Main Results:

• Various therapeutic strategies are being investigated across primary prevention, secondary prevention, and at disease onset.
• Trials include interventions like hydrolyzed casein milk formula, Bacillus Calmette-Guérin vaccine, anti-CD3 monoclonal antibodies, oral/nasal insulin, and proinsulin peptides.
• Despite challenges in long-term beta-cell function preservation, significant progress is being made in understanding disease mechanisms.

Conclusions:

• Controlled clinical trials and animal studies are advancing the understanding of beta-cell destruction in T1DM.
• Effective long-term preservation of beta-cell function remains a challenge.
• Novel therapies are crucial for preventing islet autoimmunity and halting progressive beta-cell destruction in T1DM.